Key facts
- This page summarizes Carrie L. Bourdow's Form 4 filing for Nabriva Therapeutics plc.
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 03 Aug 2022, 21:47.
Carrie L. Bourdow - 01 Aug 2022 Form 4 Insider Report for Nabriva Therapeutics plc
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 01 Aug 2022
- Net transaction value
- -$1,487
- SEC form
- 4
- Accepted by SEC
- 03 Aug 2022, 21:47:54 UTC
- Prior SEC filing
- 24 Jun 2022
- Next SEC filing
- 06 Dec 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ J. Christopher Naftzger, by power of attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Carrie L. Bourdow filed Form 4 for Nabriva Therapeutics plc on 03 Aug 2022.
Change
- Previous filing in this sequence was filed on 24 Jun 2022.
- Current net transaction value: -$1,487.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NBRV
transaction
Ordinary Shares
Sale
- Transaction value
- $1,487
- Shares
- -8,540
- Change %
- -46%
- Price
- $0.1741*
- Shares after
- 9,933
- Date
- 01 Aug 2022
- Ownership
- Direct
* marks a reported price that did not pass the local price check.